| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Most prostate cancers rely largely on the androgen-androgen receptor (AR) axis. In this study, we demonstrated the physiological signaling pathway between wild-type of AR and E2 in LNCaP cells, while the mutated AR (Thr-Ala877) expressed in the LNCaP cells has been reported to partially lose its ligand specificity and cross-react with several steroid hormones including E2. We speculate the existence of unknown regulatory mechanistic links between the AR signaling axis and E2 in LNCaP cells and other sex hormone-responsive cancer cells, and revealing these will be a novel finding. It is desirable to develop drugs targeting such cell-type-specific crosstalk between sex hormones with the ability to overcome anti-hormone resistance in certain types of prostate cancers.
|
